Literature DB >> 8416935

Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts.

S Schuldiner1, Y Liu, R H Edwards.   

Abstract

The potent antihypertensive drug reserpine inhibits the transport of biogenic amines into adrenal chromaffin granules and synaptic vesicles. Reserpine acts by binding almost irreversibly to the vesicular amine transporter, and this interaction has been used both to study the mechanism of transport and to purify the protein responsible. Recent isolation of a cDNA for the rat chromaffin granule amine transporter (CGAT) by selection in the neurotoxin 1-methyl-4-phenylpyridinium now permits an analysis of the interaction with reserpine at a molecular level. Using membranes from stable transformants expressing the transporter, we show that reserpine binds specifically and quantitatively to CGAT. As with the native protein in bovine chromaffin granules, a pH gradient accelerates reserpine binding, and amine substrates compete for binding with reserpine. However, 1-methyl-4-phenylpyridinium and tetrabenazine, the other principal inhibitor of vesicular amine transport, compete very poorly with reserpine for binding, suggesting that they interact with CGAT at distinct sites.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8416935

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

Review 1.  The role of neurotransporters in excitotoxicity, neuronal cell death, and other neurodegenerative processes.

Authors:  K P Lesch; A Heils; P Riederer
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

2.  Emulating proton-induced conformational changes in the vesicular monoamine transporter VMAT2 by mutagenesis.

Authors:  Dana Yaffe; Ariela Vergara-Jaque; Lucy R Forrest; Shimon Schuldiner
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-07       Impact factor: 11.205

3.  Expression of neurotransmitter transporters for structural and biochemical studies.

Authors:  Yael Elbaz; Tsafi Danieli; Baruch I Kanner; Shimon Schuldiner
Journal:  Protein Expr Purif       Date:  2010-06-08       Impact factor: 1.650

Review 4.  The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.

Authors:  Justin R Nickell; Kiran B Siripurapu; Ashish Vartak; Peter A Crooks; Linda P Dwoskin
Journal:  Adv Pharmacol       Date:  2014

Review 5.  Vesicular neurotransmitter transporters. Potential sites for the regulation of synaptic function.

Authors:  H Varoqui; J D Erickson
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

6.  Glutathione is involved in the granular storage of dopamine in rat PC 12 pheochromocytoma cells: implications for the pathogenesis of Parkinson's disease.

Authors:  B Drukarch; C A Jongenelen; E Schepens; C H Langeveld; J C Stoof
Journal:  J Neurosci       Date:  1996-10-01       Impact factor: 6.167

7.  The role of de novo catecholamine synthesis in mediating methylmercury-induced vesicular dopamine release from rat pheochromocytoma (PC12) cells.

Authors:  Chelsea T Tiernan; Ethan A Edwin; John L Goudreau; William D Atchison; Keith J Lookingland
Journal:  Toxicol Sci       Date:  2013-02-19       Impact factor: 4.849

Review 8.  Rauwolfia in the Treatment of Hypertension.

Authors:  Douglas Lobay
Journal:  Integr Med (Encinitas)       Date:  2015-06

Review 9.  Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons.

Authors:  Thomas S Guillot; Gary W Miller
Journal:  Mol Neurobiol       Date:  2009-03-04       Impact factor: 5.590

Review 10.  Tetrabenazine: Spotlight on Drug Review.

Authors:  Navneet Kaur; Puneet Kumar; Sumit Jamwal; Rahul Deshmukh; Vinod Gauttam
Journal:  Ann Neurosci       Date:  2016-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.